Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
RNAi screen for vemurafenib enhancer genes in BRAFV600 melanoma - Primary Screen
Assay data:790 Active, 18119 Tested
Summary
Binding affinity to SAP155 in human GM18453 cells harboring NPC1 mutant assessed as increase in 250 kDa NPC1 protein expression at 50 nM pretreated for 48 hrs followed by endoglycosidase H addition and measured after overnight incubation by Western blot analysis
Assay data:1 Tested
SummaryPubMed CitationRelated BioAssays by Target
Binding affinity to SAP155 in human GM18453 cells harboring NPC1 mutant assessed as increase in 120 kDa NPC1 protein expression at 50 nM pretreated for 48 hrs followed by PNGaseF addition and measured after overnight incubation by Western blot analysis
Assay data:1 Active, 1 Tested
SummaryCompounds, ActivePubMed CitationRelated BioAssays by Target
Binding affinity to SAP155 in human GM18453 cells harboring NPC1 mutant assessed as increase in 120 kDa NPC1 protein expression at 50 nM measured after 48 hrs by Western blot analysis
Binding affinity to SAP155 in human GM18453 cells harboring NPC1 mutant assessed as increase in 180 kDa NPC1 protein expression at 50 nM pretreated for 48 hrs followed by PNGaseF addition and measured after overnight incubation by Western blot analysis
Binding affinity to SAP155 in human GM18453 cells harboring NPC1 mutant assessed as increase in 180 kDa NPC1 protein expression at 50 nM pretreated for 48 hrs followed by endoglycosidase H addition and measured after overnight incubation by Western blot analysis
Binding affinity to SAP155 in human GM18453 cells harboring NPC1 mutant assessed as increase in 100 kDa NPC1 protein expression at 50 nM pretreated for 48 hrs followed by endoglycosidase H addition and measured after overnight incubation by Western blot analysis relative to control
Binding affinity to SAP155 in human GM18453 cells harboring NPC1 mutant assessed as increase in 100 kDa NPC1 protein expression at 50 nM measured after 48 hrs by Western blot analysis
Binding affinity to SAP155 in human GM18453 cells harboring NPC1 mutant assessed as increase in 180 kDa NPC1 protein expression at 50 nM measured after 48 hrs by Western blot analysis
Binding affinity to SAP155 in human GM18407 cells harboring NPC1 R404Q/M1142T mutant assessed as restoration of cholesterol trafficking at 0.001 to 5 uM after 48 hrs by filipin-staining based fluorescence microscopic analysis
Assay data:4 Tested
Binding affinity to SAP155 in human GM18453 cells harboring NPC1 mutant assessed as restoration of cholesterol trafficking at 50 nM after 48 hrs by filipin-staining based fluorescence microscopic analysis
Assay data:4 Active, 4 Tested
A screen to identify synergistic combinations in colorectal cancer - Primary Screen (SW620)
Assay data:15 Active, 794 Tested
SummaryPubMed CitationRelated BioAssays by Depositor
A screen to identify synergistic combinations in colorectal cancer - Primary Screen (SNUC5)
Assay data:11 Active, 794 Tested
A screen to identify synergistic combinations in colorectal cancer - Secondary Screen (DIFI)
Assay data:96 Active, 160 Tested
A screen to identify synergistic combinations in colorectal cancer - Secondary Screen (HT115)
Assay data:88 Active, 160 Tested
A screen to identify synergistic combinations in colorectal cancer - Secondary Screen (COLO320HSR)
Assay data:11 Active, 160 Tested
A screen to identify synergistic combinations in colorectal cancer - Secondary Screen (SW1116)
Assay data:122 Active, 160 Tested
A screen to identify synergistic combinations in colorectal cancer - Secondary Screen (LS180)
Assay data:67 Active, 160 Tested
A screen to identify synergistic combinations in colorectal cancer - Primary Screen (HCT15)
Assay data:18 Active, 794 Tested
A screen to identify synergistic combinations in colorectal cancer - Primary Screen (CAR1)
Assay data:9 Active, 794 Tested
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on